Stockholders Approve 100% Increase in Authorized Shares, Doubling Future Dilution Capacity

summarizeSummary

CytomX Therapeutics' stockholders approved a 100% increase in authorized common stock to 600 million shares, significantly expanding the company's capacity for future capital raises and employee equity programs, but also introducing substantial potential dilution.

check_boxKey Events

• Authorized Common Stock Doubled

  Stockholders approved an amendment to the Certificate of Incorporation, increasing the authorized number of common shares from 300,000,000 to 600,000,000. This was filed on June 22, 2026, following stockholder approval on June 17, 2026.

• Equity Incentive Plan Expanded

  The 2015 Equity Incentive Plan was amended to increase the shares authorized for issuance by 6,500,000 shares, approved by stockholders on June 17, 2026.

• Employee Stock Purchase Plan Expanded

  The Employee Stock Purchase Plan (ESPP) was amended to increase the shares authorized for issuance by 1,000,000 shares, approved by stockholders on June 17, 2026.

• Annual Meeting Results

  All proposals at the Annual Meeting on June 17, 2026, were approved, including the election of directors, ratification of the auditor, and the aforementioned share authorizations.

auto_awesomeAnalysis

CytomX Therapeutics' stockholders have approved a substantial increase in the company's authorized common stock, doubling it from 300 million to 600 million shares. This move provides the company with significant flexibility for future capital raises, strategic partnerships, or employee equity compensation. However, it also introduces the potential for considerable dilution for existing shareholders. With 217.7 million shares currently outstanding, the newly authorized shares represent a potential dilution of over 175% if fully utilized. This authorization follows a recent $234.2 million public offering, indicating a proactive strategy for long-term capital management rather than immediate financial distress.